Where Azenta Stands With Analysts
Throughout the last three months, 7 analysts have evaluated Azenta (NASDAQ:AZTA), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 1 | 0 | 0 |
| Last 30D | 2 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $43.43, a high estimate of $50.00, and a low estimate of $39.00. This current average reflects an increase of 11.76% from the previous average price target of $38.86.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of Azenta among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matthew Stanton | Jefferies | Lowers | Buy | $40.00 | $42.00 |
| David Saxon | Needham | Maintains | Buy | $44.00 | $44.00 |
| Brendan Smith | TD Cowen | Raises | Hold | $39.00 | $35.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $50.00 | $34.00 |
| David Saxon | Needham | Raises | Buy | $44.00 | $42.00 |
| Andrew Cooper | Raymond James | Raises | Outperform | $45.00 | $35.00 |
| David Saxon | Needham | Raises | Buy | $42.00 | $40.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Azenta. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Azenta compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Azenta's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Azenta's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Azenta analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Azenta's Background
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
Unraveling the Financial Story of Azenta
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Azenta's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 5.21%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Azenta's net margin excels beyond industry benchmarks, reaching 31.98%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Azenta's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.99%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Azenta's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.49%, the company showcases efficient use of assets and strong financial health.
Debt Management: Azenta's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Significance of Analyst Ratings Explained
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.